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To evaluate changes in functional connectivity as a result of treatment with antipsychotic
drugs (APDs) in subjects with schizophrenia (SZ), we identified a limited number of regions
that have been implicated in the mechanism of action of APDs and that are part of a neu-
ronal network known to be modulated by dopamine (DA). These regions consisted of the
nucleus accumbens (NAcc), the hippocampus (Hip), and the medial frontal cortex (MFC). SZ
participants were blindly randomized into a haloperidol treatment group (n=12) and an olan-
zapine treatment group (n=17). Using PET with 15O, we evaluated changes in functional
connectivity between these regions during rest and task performance at three treatment
time points: (1) at baseline, after withdrawal of all psychotropic medication (2 weeks), (2)
after 1 week on medication, and (3) after 6 weeks on medication. Results from the two
treatment groups were combined during analysis to investigate the common effects of
APDs on functional connectivity. We found that the functional connectivity between MFC
and NAcc significantly increased at week one, and then significantly decreased from week
one to week 6. The functional connectivity between MFC and Hip significantly decreased
at week one and week 6 relative to baseline. Critically, the strength of the functional con-
nectivity between the MFC and Hip after 1 week of treatment was predictive of treatment
response.This pattern of changes may represent an important biomarker for indexing treat-
ment response.The regulation by APDs of the balance between prefrontal and limbic inputs
to the striatum may be crucial to restoring adaptive behavior.
Keywords: antipsychotic drugs, schizophrenia, functional connectivity, nucleus accumbens, hippocampus, medial
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INTRODUCTION
There are a number of antipsychotic drugs (APDs) available
to treat schizophrenia (SZ). All current APDs are known to be
dopamine D2 antagonists, and D2 blockade is believed to be a
major part of their mechanism of action (Creese et al., 1976). First-
generation APDs are characterized by predominant dopaminergic
blockade, while second-generation APDs block both dopaminer-
gic and serotoninergic receptors (Lahti et al., 1996). APDs pri-
marily relieve the positive symptoms of SZ (such as hallucinations
and delusions), and recent studies have shown that most first- and
second-generation APDs alleviate positive symptoms with sim-
ilar efficacy (Lieberman et al., 2005; McEvoy et al., 2006). Two
meta-analyses have set out to characterize the time course of the
response to APDs: one found that the greatest reduction of posi-
tive symptoms occurred in the first and second weeks of treatment,
with a continued improvement over time afterwards (Agid et al.,
2003), and the other found a linear reduction of positive symptoms
over the course of, and up to 28 days of treatment (van den Oord
et al., 2009). Both studies agree that the therapeutic response to
APDs develops on a timescale of several weeks, but the mechanism
of action of APDs is still poorly understood. This timescale
implies an association between APD response and changes in
neuronal connections. In this study, we investigated functional
changes in neuronal connectivity using H215O positron emission
tomography (PET).
Functional connectivity can be evaluated using H215O PET or
functional magnetic resonance imaging (fMRI), and is defined as
a correlation in activity between two different brain areas (Biswal
et al., 1995). It has been repeatedly shown to reflect the under-
lying structural connectivity of the brain (Helmich et al., 2010),
although it is variable and can exist between regions without direct
structural links (van den Heuvel et al., 2009). A current theory of
the pathophysiology of SZ is the dysconnection hypothesis, pro-
posed by Friston and Frith (1995), which argues that the changes
observed in SZ are due to abnormal interactions between brain
areas. Lending support to this hypothesis, several studies have
found differences in functional connectivity between persons with
SZ and healthy controls (Schlosser et al., 2003; Meyer-Lindenberg
et al., 2005; Liang et al., 2006; Garrity et al., 2007; Zhou et al., 2007;
Whitfield-Gabrieli et al., 2009).
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While SZ is known to alter functional connectivity, the effects
of APDs on functional connectivity are not fully understood. Only
two studies have evaluated functional connectivity changes in rela-
tion to APD treatment (Sambataro et al., 2009; Liu et al., 2010).
Liu and colleagues used fMRI to evaluate changes in whole brain
functional connectivity. Sambataro et al. used fMRI during task
performance to examine functional connectivity changes within
the default mode network. Neither study assessed differences in
functional connectivity between an unmedicated time point and
the early stages of treatment.
Our approach was to evaluate functional connectivity between
a limited number of regions at three time points in treatment:
before treatment, in the early stages of treatment, and after 6 weeks
of treatment, at which time they were assumed to have reached
a plateau in treatment response (van den Oord et al., 2009).
The nucleus accumbens (NAcc), the hippocampus (Hip), and the
medial frontal cortex (MFC) have been implicated in the mech-
anism of action of APDs (Berridge and Robinson, 1998). Our
prior studies also suggest that these regions are involved in the
mechanism of APD action (Lahti et al., 2006, 2009), and they are
known to be part of a neural network modulated by dopamine
(Kelley and Berridge, 2002), and therefore likely affected by APDs.
The network defined by these regions is central to the model pro-
posed by Goto and Grace (2008), which accounts for the role of
DA in regulating the balance between limbic and prefrontal dri-
ves in the NAcc. Using in vivo electrophysiological recordings in
the rat brain, Goto and Grace (2005) found that manipulations
of DA released in the NAcc modulate hippocampal and cortical
inputs; these experiments formed the basis of a model for how
the disruption of DA can underlie a major psychiatric illness, such
as SZ.
The model of Goto and Grace (2008) predicts APD treatment
will alter the functional connectivity of MFC, NAcc, and Hip in
specific ways. In particular, this model predicts that APD treat-
ment should increase the functional connectivity between MFC
and NAcc and decrease functional connectivity between MFC and
Hip. Using PET with 15O,we tested the predictions of this model in
patients before and after APD treatment. We chose to study a com-
bination of patients treated with either a first or second generation
APD, because we were interested in the changes to connectivity
due to the drugs’ effects on the D2 receptors specifically (assumed
to be common between first and second generation drugs). We
evaluated the time course of regional cerebral blood flow (rCBF)
patterns that developed after 1 and 6 weeks of treatment with
either a first (haloperidol) or a second generation (olanzapine)
APD in patients with SZ. Based on the model of Goto and Grace,
we hypothesized that APD treatment would acutely increase the
strength of the relationship between the MFC and NAcc. We fur-
ther hypothesized that the magnitude of the change in functional
connectivity between these regions would increase with increasing
treatment duration, and that distinctive changes would be seen in
the early (1 week) and later (6 week) stages of treatment.
MATERIALS AND METHODS
PARTICIPANTS
This analysis includes resting-state imaging data previously
reported in Lahti et al. (2009) and previously unpublished data
acquired as part of the same project. Thirty-seven physically
healthy individuals with SZ were recruited from the Residen-
tial Research Unit of the Maryland Psychiatric Research Center
(MPRC) in Baltimore, MD, to participate in this study. Participants
were selected from those who had been diagnosed with SZ by two
independent research psychiatrists using DSM-IV criteria, based
on the Structured Clinical Interview for DSM-III-R (SCID; Spitzer
et al., 1992) and the patients’ clinical histories. All participants
had been on stable doses of APDs; no patient had been treated
with a long-acting APD depot preparation. Only patients deemed
capable of understanding the risks of the study were selected to
participate. All participants provided informed consent to a Uni-
versity of Maryland IRB-approved protocol. Details of the consent
procedure can be found in Lahti et al. (2009).
Thirty-seven patients initially provided informed consent;
however, eight dropped out during the study period [details of
participant drop out were reported in Lahti et al. (2009)]. Partic-
ipants ranged in age from 19 to 60 years, and duration of illness
ranged from 1 to 44 years. The study cohort included 22 males
and 7 females, and 8 Caucasians and 21 African Americans. All
study participants remained in the inpatient research unit for the
duration of the study. Participants were withdrawn from all psy-
chotropic medications for 2 weeks before initiating PET scanning.
This medication-free period allowed for the washout of APDs
from central dopamine D2 receptors (Tamminga et al., 1993), and
a baseline level of symptoms was evaluated for each participant
using the Brief Psychiatric Rating Scale (BPRS, 1–7 scale; Overall
and Gorham, 1962).
TREATMENT
Following the medication washout period, study participants
were blindly randomized into one of the following four groups:
(1) 10 mg fixed dose of haloperidol for 6 days, followed by a
clinically determined optimal dose of haloperidol (10–20 mg)
for 5 weeks; (2) 12.5 mg fixed dose of olanzapine for 6 days,
followed by a clinically determined optimal dose of olanzap-
ine (12.5–25 mg) for 5 weeks; (3) placebo for 6 days followed
by a clinically determined optimal dose of haloperidol (10–
20 mg) for 5 weeks; or (4) placebo for 6 days followed by a clin-
ically determined optimal dose of olanzapine (12.5–25 mg) for
5 weeks. Medications were prepared in similar-looking capsules
by the hospital pharmacist. Optimal dose was determined by
treating psychiatrists, who blindly adjusted medication in pre-
determined increments (5 mg haloperidol, 6 mg olanzapine). Par-
ticipants were placed on anticholinergic medication as treating
psychiatrists deemed necessary. After the first week of the study,
all patients were on an optimal dose of either haloperidol or
olanzapine.
There were no statistically significant differences between treat-
ment groups in age (38.3± 12.2 vs. 36.1± 10.5 years), length of
illness (15.3± 14.1 vs. 11.3± 9.6 years), gender (male/female; 10/2
vs. 12/5), and race ratio (Caucasian/African American; 5/7 vs.
3/14). For details of treatment dosages, refer to Lahti et al. (2009).
Because we were specifically interested in changes to functional
connectivity due to the common effects of APDs on D2 recep-
tors, we combined treatment groups for all analyses. Our goal
was to determine the common effect of APD treatment, as both
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first- and second-generation APDs have been found to decrease
positive symptoms equivalently (Lieberman et al., 2005; McEvoy
et al., 2006), and our previous study of this data reported similar
rCBF changes in the MFC, NAcc, and Hip between medication
groups (Lahti et al., 2009). Week one scans from participants
receiving a placebo for the first 6 days were not included in our
analysis, and, as treatment response has been shown to plateau
after 4 weeks (van den Oord et al., 2009), patients from all treat-
ment groups were deemed to have reached optimal response by
week six of treatment.
EXPERIMENTAL DESIGN
Participants were evaluated during three sessions over the course of
treatment: (1) at baseline, before restarting APD treatment, (2) at
1 week, after 6 days of treatment, and (3) at 6 weeks, after 6 weeks
of treatment. At each session, participants were scanned using
H215O PET during three task conditions, as we were interested
in changes in functional connectivity due to APDs that occurred
independent of task (i.e., due to state not context). The H215O
PET scans were then repeated during all task conditions, for a total
of six H215O PET scans per session (two for each task condition
per session). Additionally, participants’ symptoms were evaluated
using the BPRS at each session.
EXPERIMENTAL CONDITIONS
Participants received H215O PET scans during the following task
conditions, which vary widely in terms of the networks they
involve (Greicius et al., 2003): (1) at rest with eyes open, (2)
during a sensorimotor control task, and (3) during an auditory
discrimination task.
In the sensorimotor control task (SMC), participants were pre-
sented with 60 trials of either a high frequency tone (1500 Hz) or
a low frequency tone (800–1492 Hz) of 100 ms duration. Partici-
pants were instructed to alternate between pressing a button held
in their right hand and pressing a button held in their left hand
when they heard the tone. Sixty tones were presented during each
task. The inter-trial interval between the onset of the first tone and
the onset of the next tone was 2 s.
The auditory discrimination task (DEC) was a graded error
rate, forced choice task, described previously by Holcomb et al.
(2000). In this task, participants were presented with 60 trials of
either a high frequency tone (1500 Hz) or a low frequency tone
(800–1492 Hz) of 100 ms duration. Participants were instructed
to immediately press a button held in their right hand when they
recognized a higher frequency tone or to press a button held in
their left hand when they recognized a lower frequency tone.
Sixty high and low frequency tones were presented during each
task. The inter-trial interval between the onset of the first tone
and the onset of the next tone was 2 s. Failure to respond was
scored as an error, and the pitch difference was adjusted such that
participants made the correct choice approximately 80% of the
time. To control for potential changes in functional connectivity
due to learning, participants were trained extensively on the DEC
upon study enrollment (2 weeks prior to the first imaging ses-
sion) until they consistently achieved the required performance
accuracy. Participants were retrained immediately prior to each
scanning session.
ANALYSIS OF TASK PERFORMANCE
Task response accuracies and reaction times were compared
between sessions using an analysis of variance (ANOVA) with
Bonferroni correction for multiple comparisons.
PET SCANNING
Participants were scanned on a GE Advanced 3D PET system,
located at the PET Center of the Johns Hopkins Hospital. Each
90 s scan acquired 30 parallel slices with a center-to-center separa-
tion of 5 mm, an average transaxial resolution of 5 mm full width
at half maximum (FWHM), and an average resolution of 6 mm
FWHM in the center of the field of view. At the beginning of
each session, a single 10 min transmission scan was acquired for
attenuation correction using a 10 mCi 68 Ge rotating pin source.
A 12 mCi H215O contrast bolus was then administered, using
the method described by Raichle et al. (1983), without arterial
blood sampling. Data acquisition began 15 s after bolus admin-
istration and continued for 90 s. Each scan resulted in one raw,
three dimensional rCBF PET image corresponding to a specific
task condition.
PET IMAGE PREPROCESSING
The raw PET rCBF images were preprocessed using statistical para-
metric mapping routines (SPM2; Friston et al., 1996) in the fol-
lowing manner:(1) all images from each participant were realigned
to that participant’s first image, (2) all images were transformed
into the standard Montreal Neurologic Institute (MNI) anatom-
ical space, and (3), all images were spatially smoothed using a
12-mm full width at half maximum Gaussian kernel.
ANALYSIS OF APD EFFECTS ON rCBF
SPM8 was used to evaluate rCBF changes associated with APD
treatment. Participants’ week one preprocessed rCBF PET images
were compared to their baseline preprocessed rCBF PET images
using a paired t -test to determine changes associated with 1 week
of APD treatment. Participant’s week six preprocessed rCBF PET
images were compared to their baseline preprocessed rCBF PET
images using a paired t -test to determine changes associated with
6 weeks of APD treatment. Participant’s week six preprocessed
rCBF PET images were compared to their week one preprocessed
rCBF PET images using a paired t -test to determine changes
between 1 and 6 weeks of APD treatment. Regions showing sig-
nificant change with treatment were identified using p< 0.05,
corrected using false discovery rate correction applied at the
cluster-level.
ANALYSIS OF APD EFFECTS ON FUNCTIONAL CONNECTIVITY
Preprocessed rCBF PET images from all participants were grouped
into four-dimensional (4D) vectors corresponding to each task
condition at each session; preprocessed rCBF PET images were
also combined into one “all tasks” condition for each session.
This resulted in four 4D vectors from each session (12 vectors
total).
Regions of interest (ROIs) were anatomically defined as masks
in MNI space as follows: bilateral ROIs corresponding to the hip-
pocampi were defined using the right and left hippocampus masks
from the Automated Anatomical Labeling (AAL) atlas in PickAtlas
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(Maldjian et al., 2003); bilateral ROIs corresponding to the NAcc
were hand traced in MNI space as described by Ballmaier et al.
(2004); single ROI corresponding to the MFC was created by plac-
ing a 10-mm sphere at (−1, 47, −4), coordinates identified by
Whitfield-Gabrieli et al. (2009). Additionally, a single mask of the
whole brain was created using PickAtlas (29) to determine total
intracranial activation.
Regions of interest masks were used to extract the first eigen-
variate of the rCBF signal corresponding to that ROI from each
of the 4D vectors. Functional connectivity between two ROIs
was defined as the partial correlation between the rCBF signal
eigenvariates from those ROIs, controlling for total intracranial
activation, and was calculated for all conditions during all ses-
sions. The resulting partial correlation coefficients (r scores) were
transformed using Fisher’s r to z transformation into z-scores (Fox
et al., 2005) for display and comparison.
SPSS was used to assess the effects of APDs on functional
connectivity in the combined “all tasks” condition, such that if
they showed correlated patterns of activity they were consid-
ered to be functionally connected. For each connection between
two ROIs, the connection z-score from week one was com-
pared to the connection z-score from baseline using a paired
t -test to determine changes in functional connectivity asso-
ciated with 1 week of APD treatment. Similarly, the connec-
tion z-score from week six was compared to the connection
z-score from baseline and the connection z-score from week
six was compared to the connection z-score from week one.
Regions showing significant change with treatment were identified
using the Hochberg-adjusted p< 0.05 (Benjamini and Hochberg,
1995).
ASSOCIATION BETWEEN TREATMENT RESPONSE AND FUNCTIONAL
CONNECTIVITY
Treatment response was defined to be the change in BPRS Psy-
chosis Subscale score from baseline (before initiating treatment)
to the end of the study (following 6 weeks of continuous APD treat-
ment). To examine the relationship between treatment response
and functional connectivity, the correlation between treatment
response and functional connectivity (z-scores) was calculated for
each session (at baseline, week one, and week six of treatment).
RESULTS
There were no significant differences between scanning sessions
for response error rate or reaction time for the SMC or DEC (all
p> 0.5). This suggests that any changes related to the tasks over
time were not related to learning.
APD EFFECTS ON rCBF AFTER 1WEEK OF TREATMENT
Figure 1 shows that, for all tasks, significant localized increases
and decreases in rCBF relative to baseline were observed after
1 week of treatment. The most significant effects observed at
week one were bilateral increases in rCBF in the striatum (clus-
ter pFDR corrected< 0.001) and decreases in MFC. The clusters
in the striatum were extensive and encompassed the NAcc and
putamen. The peak activation was observed in the putamen.
Activation peaks from each task condition are summarized in
Tables 1–3.
APD EFFECTS ON rCBF AFTER 6WEEKS OF TREATMENT
Also seen in Figure 1 are localized changes in rCBF relative
to baseline after 6 weeks of treatment. The most significant
increases in rCBF were again observed in the striatum (clus-
ter pFDR corrected< 0.001). As in the results at week one, the
clusters were largely coextensive with NAcc and putamen. Sig-
nificantly decreased rCBF was observed in MFC (cluster pFDR
corrected< 0.001). The peak rCBF decreases were observed in
the medial frontal gyrus. Deactivation was also observed in the
medial temporal lobes bilaterally. Activation peaks from each task
condition are summarized in Tables 1–3.
APD EFFECTS ON rCBF BETWEEN 1 AND 6WEEKS OF TREATMENT
There were increases in rCBF in the thalamus at week six relative to
week one (cluster pFDR corrected< 0.001) and decreases in rCBF
in the putamen, MFC (cluster pFDR corrected< 0.001), and in
the hippocampi (cluster pFDR corrected< 0.05).
In all tasks, APDs led to significantly decreased rCBF at both
1 and 6 weeks in the MFC. Importantly, there was a shift over
time of the deactivation locus from the anterior cingulate to
more rostral MFC. This deactivation shift was pronounced in
the DEC task, as shown in Figure 2, where there was a rela-
tive increase in activation in the anterior cingulate, and a relative
decrease in activation in MFC at week six relative to week one.
Activation peaks from each task condition are summarized in
Tables 1–3.
APD EFFECTS ON FUNCTIONAL CONNECTIVITY
Pair-wise functional connectivity estimates between the MFC, the
NAcc, and the Hip at baseline (off medication), after one and
6 weeks of treatment for each of the scan conditions (rest, SMC,
and DEC), and for the combined scan conditions are shown
in Figure 3. The coefficients of correlation are presented in
Tables 4–6 for the combined data, and in Tables 7–9 for each
of the individual conditions. For the combined tasks at baseline,
there was significant functional connectivity between the MFC
and the Hip bilaterally, between the NAcc and the Hip bilater-
ally, between the MFC and the left NAcc, and between the right
and left NAcc. For the combined tasks at week one, there was sig-
nificant functional connectivity between the MFC and left NAcc,
between the NAcc and Hip bilaterally, and between the MFC and
left Hip. For the combined tasks at week six, there was signifi-
cant functional connectivity between the right and left NAcc and
between the right and left Hip. A similar pattern of functional con-
nectivity, albeit reduced, was observed across the individual task
conditions. We observed that the left and right Hip had consis-
tently high functional connectivity, supporting results previously
reported by other groups (Stein et al., 2000). Significant func-
tional connectivity between NAcc and the contralateral Hip was
never observed.
We observed the following changes in functional connec-
tivity for the combined tasks over time (as illustrated in
Figure 4): (1) after 1 week of treatment, the functional con-
nectivity between MFC and the left NAcc increased relative to
baseline (p< 0.05). The strong baseline connectivity between
MFC and right Hip was reduced significantly (p< 0.05). (2)
After 6 weeks of treatment, there was a significant decrease in
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FIGURE 1 | rCBF changes relative to baseline with APD treatment
after 1 and 6weeks of treatment. Increases in activation are shown in
red and decreases are shown in blue. No significant changes were seen in
the placebo-treated group at week 1 for any task. In the APD-treated
group, there were significant increases in activation in NAcc after
treatment with APDs (arrows, horizontal sections). There was a significant
decrease in activation in medial frontal areas that shifted rostrally and
dorsally between week 1 and week 6 of treatment (arrows, sagittal and
coronal sections). The activation decrease was most significant during the
sensory motor (SMC) and decision (DEC) task conditions. Coronal slices
y = 47 mm and horizontal slices z =−10 mm (Montreal Neurological
Institute coordinate system).
functional connectivity between MFC and bilateral Hip (p< 0.05)
relative to baseline, and a significant decrease in the functional
connectivity between the right NAcc and ipsilateral Hip rel-
ative to baseline. (3) After 6 weeks of treatment, there were
significant reductions in MFC-left NAcc functional connectiv-
ity relative to week one (p< 0.05). There was also a trend
(p= 0.07) towards a significant decrease in the functional con-
nectivity between the MFC and the left Hip. Significant changes
in functional connectivity between time points are listed in
Table 10.
ASSOCIATION BETWEEN TREATMENT RESPONSE AND FUNCTIONAL
CONNECTIVITY
To quantify treatment response, the change in BPRS Psychosis
subscale score from baseline to week six was calculated for each
participant. This score was positively correlated with the func-
tional connectivity between the MFC and left Hip (r2= 0.219,
p< 0.05) at 1 week of treatment, and negatively correlated with
the functional connectivity between the right NAcc and right Hip
(r2= 0.109, p< 0.05) at 6 weeks of treatment. These results sug-
gest that functional connectivity between MFC and left Hip may
be predictive of treatment response.
DISCUSSION
The present study found that APDs alter the activation and
functional connectivity between the MFC, NAcc, and Hip after
1 week of treatment, and that further changes unfold over the
next 5 weeks. As predicted, the functional connectivity between
MFC and NAcc significantly increased at week one. However, this
was followed by a significant decrease in functional connectivity
between these regions from week one to week six. The functional
connectivity between MFC and Hip significantly decreased at week
one and week six relative to baseline. Critically, the strength of the
functional connectivity between MFC and Hip after 1 week of
www.frontiersin.org December 2012 | Volume 3 | Article 105 | 5
Bolding et al. Antipsychotic drugs alter functional connectivity
Table 1 | Rest condition.
Region Hemisphere Cluster peak
coordinatesa
Pb kE
Rest rCBF increases following 1 week of APD treatment, SZ1>SZ0
Putamen R 24, 14, 0 0.000 112
Putamen L −30, 4, −4 0.000 138
Rest rCBF increases following 6 weeks of APD treatment, SZ6>SZ0
Putamen R 24, 8, −6 0.000 275
Putamen L −36, −6, 2 0.003 84
rCBF decreases following 6 weeks of APD treatment, SZ6<SZ0
Medial frontal gyrus L, R −2, 54, 26 0.003 76
aMontreal neurological institute (MNI) anatomical coordinates in x, y, z.
bp values FDR corrected.
SZ0, baseline; SZ1, after 1 week of antipsychotic drugs treatment; SZ6, after
6 weeks of antipsychotic drug treatment; APDs, antipsychotic drugs; R, right; L,
left; kE, kernel extent in voxels; rCBF, regional cerebral blood flow.
Regional cerebral blood flow changes during rest from baseline after 1 and
6 weeks of treatment and between 1 and 6 weeks of treatment.
Table 2 | Sensory motor task condition.
Region Hemisphere Cluster peak
coordinatesa
Pb kE
SMC task rCBF increases following 1 week of APD treatment, SZ1>SZ0
Putamen L −32, 2, −4 0.002 108
SMC task rCBF increases following 6 weeks of APD treatment, SZ6>SZ0
Putamen R 24, 4, −4 0.000 282
Putamen L −36, −2, −2 0.005 55
aMontreal neurological institute (MNI) anatomical coordinates in x, y, z.
bp values FDR corrected.
SZ0, baseline; SZ1, after 1 week of antipsychotic drugs treatment; SZ6, after
6 weeks of antipsychotic drug treatment; APDs, antipsychotic drugs; R, right; L,
left; kE, kernel extent in voxels; rCBF, regional cerebral blood flow.
Regional cerebral blood flow changes during sensorimotor control task from
baseline after 1 and 6 weeks of treatment and between 1 and 6 weeks of
treatment.
treatment was predictive of treatment response, explaining 21%
of the variance in BPRS Psychosis subscale score changes between
baseline and week six. Across a range of cognitive tasks, APDs
significantly increased rCBF in striatum after 1 and 6 weeks of
treatment. APDs also led to significantly decreased rCBF in the
MFC at weeks one and six relative to baseline, with the deactiva-
tion locus shifting to more rostral and ventral MFC from week
one to week six. Likewise, APDs led to significant rCBF changes
in Hip.
FUNCTIONAL CONNECTIVITY
Functional connectivity, defined as a measure of the “statistical
dependencies among remote neurophysiological events” (Friston
et al., 2007), is increasingly used to investigate the organization
of the brain. Compared to healthy controls, changes in functional
Table 3 | Decision task condition.
Region Hemisphere Cluster peak
coordinatesa
Pb kE
DEC task rCBF increases following 1 week of APD treatment, SZ1>SZ0
Putamen L −26, 6, −6 0.000 646
Putamen R 30, 14, −6 0.000 132
Putamen R 28, 6, −6 0.021 41
DEC task rCBF decreases following 1 week of APD treatment, SZ1<SZ0
Anterior cingulate cortex L, R 4, 10, 40 0.037 41
DEC task rCBF increases following 6 weeks of APD treatment, SZ6>SZ0
Putamen L −36, −4, −4 0.000 153
Putamen R 24, 6, −2 0.000 150
Putamen L −18, 14, −8 0.006 60
DEC task rCBF decreases following 6 weeks of APD treatment, SZ6<SZ0
Medial frontal gyrus L, R 0, 50, 18 0.011 53
DEC task rCBF increases between week 1 and week six of
APD treatment, SZ6<SZ1
Putamen L −26, 4, −6 0.005 55
aMontreal Neurological Institute (MNI) anatomical coordinates in x, y, z.
bp values FDR corrected.
SZ0, baseline; SZ1, after 1 week of antipsychotic drugs treatment; SZ6, after
6 weeks of antipsychotic drug treatment; APDs, antipsychotic drugs; R, right; L,
left; kE, kernel extent in voxels; rCBF, regional cerebral blood flow.
Regional cerebral blood flow changes during decision task from baseline after 1
and 6 weeks of treatment and between 1 and 6 weeks of treatment.
connectivity in SZ have been reported by multiple groups (Lawrie
et al., 2002; Schlosser et al., 2003; Meyer-Lindenberg et al., 2005;
Liang et al., 2006; Bluhm et al., 2007; Zhou et al., 2007; Whitfield-
Gabrieli et al., 2009; Lynall et al., 2010; Salvador et al., 2010).
Notably, Salvador et al. (2010) reported an increased functional
connectivity at rest between the MFC and the caudate in chronic,
medicated individuals with SZ with respect to normal volunteers,
and Meyer-Lindenberg et al. (2005) observed abnormal functional
connectivity between the dorsolateral prefrontal cortex and the
Hip in medication-free patients with SZ during performance of a
working memory task. Our findings extend the work of Salvador
and Meyer-Lindenberg and colleagues by showing that APDs mod-
ify the functional connectivity between MFC and Hip and between
MFC and NAcc.
Prior to our investigation, only two groups have reported
changes in functional connectivity with APD treatment (Sambat-
aro et al., 2009; Liu et al., 2010).However, neither group investi-
gated the acute changes in functional connectivity such as those
found in this study. Lui et al. (2010) reported that 6 week APD
treatment in APD-naïve individuals with SZ resulted in a wide-
spread attenuation of functional connectivity, including between
the caudate and the PFC, and between the PFC and the parahip-
pocampus. Sambataro et al. (2009) reported increased connectiv-
ity between the ventromedial PFC and the rest of the default mode
network after 8 vs. 4 weeks of treatment with olanzapine; however,
the patients were not studied while medication-free. Thus, our
study extends these findings by reporting both an acute increase
Frontiers in Psychiatry | Schizophrenia December 2012 | Volume 3 | Article 105 | 6
Bolding et al. Antipsychotic drugs alter functional connectivity
Table 4 | Functional connectivity between regions of interest during all
three task conditions at baseline.
Areaa MFC LNAcc RNAcc LHIP RHIP
MFC 1.000
LNAcc 0.339
p=0.002**
1.000
RNAcc −0.018
p=0.874
0.262
p=0.018* 1.000
LHIP 0.344
p=0.002**
0.304
p=0.006*
−0.115
p=0.305
1.000
RHIP 0.477
p=0.000**
0.092
p=0.414
−0.277
p=0.012*
0.740
p=0.000**
1.000
aValues reported are Pearson’s r and two-tailed significance, with 79 degrees
of freedom. *p<0.05, **p<0.005. PFC, prefrontal cortex; LNAcc, left nucleus
accumbens, RNAcc, right nucleus accumbens; LHIP, left hippocampus; RHIP, right
hippocampus.
and decrease in functional connectivity between the MFC and
NAcc and between the MFC and Hip, respectively, in association
with APD.
Relevant to the study of APDs, changes in functional connec-
tivity of resting-state fMRI have also been observed in conjunc-
tion with the dopamine precursor, l-dopa (Kelly et al., 2009).
Acute l-dopa administration in healthy participants increased
functional connectivity between the NAcc and ventrolateral PFC,
whereas diet-induced DA depletion perturbed fronto-striatal
functional connectivity during performance of the Wisconsin
Card Sorting Task (Nagano-Saito et al., 2008). In participants
with Parkinson’s disease compared to healthy participants, there
was a remapping of cerebral connectivity that reduced the spa-
tial segregation between different cortico-striatal loops (Helmich
et al., 2010). Thus, changes in fronto-striatal functional connec-
tivity have been observed with both DA antagonists and ago-
nists, and in situations of DA depletion either in Parkinson’s
disease or diet-induced. These findings are additional evidence
that manipulations of DA levels in the NAcc can have signifi-
cant effects on functional connectivity such as the changes we
observed.
THE MFC-NAcc-HIP NETWORK
The neuronal network examined in this study (Figure 5) includes
the MFC, NAcc, and Hip, which have been implicated in the
mechanism of action of APDs. Imaging studies have consistently
demonstrated that first- and second-generation APDs increase
functional activity in the striatum (Holcomb et al., 1996; Lahti
et al., 2005, 2009). In addition, lower pre-treatment striatal meta-
bolic rate (Buchsbaum et al., 1992) and greater post-treatment
striatal activation have been shown to predict treatment response
(Buchsbaum et al., 1992; Lahti et al., 2009). Likewise, changes
in ACC (Ngan et al., 2002; Lahti et al., 2009) and hippocampal
(Liddle et al., 2000; Medoff et al., 2001; Lahti et al., 2003, 2009)
activation following first- and second-generation APD treatment
have been reported and found to be correlated with or to predict
response. Taken together, these studies point to the importance of
Table 5 | Functional connectivity between regions of interest during all
three task conditions at week one.
Areaa MFC LNAcc RNAcc LHIP RHIP
MFC 1.000
LNAcc 0.573
p=0.000**
1.000
RNAcc 0.023
p=0.869
0.249
p=0.072
1.000
LHIP 0.329
p=0.016*
0.383
p=0.005**
−0.163
p=0.245
1.000
RHIP 0.056
p=0.692
0.122
p=0.383
−0.400
p=0.003**
0.716
p=0.000**
1.000
aValues reported are Pearson’s r and two-tailed significance, with 51 degrees
of freedom. *p<0.05, **p<0.005. PFC, prefrontal cortex; LNAcc, left nucleus
accumbens, RNAcc, right nucleus accumbens; LHIP, left hippocampus; RHIP, right
hippocampus.
Table 6 | Functional connectivity between regions of interest during all
three task conditions at week six.
Areaa MFC LNAcc RNAcc LHIP RHIP
MFC 1.000
LNAcc 0.222
p=0.054
1.000
RNAcc 0.104
p=0.373
0.391
p=0.000**
1.000
LHIP 0.068
p=0.558
0.443
p=0.000**
−0.057
p=0.626
1.000
RHIP −0.126
p=0.276
0.096
p=0.411
−0.553
p=0.000**
0.666
p=0.000**
1.000
aValues reported are Pearson’s r and two-tailed significance, with 74 degrees
of freedom. *p<0.05, **p<0.005. PFC, prefrontal cortex; LNAcc, left nucleus
accumbens, RNAcc, right nucleus accumbens; LHIP, left hippocampus; RHIP, right
hippocampus.
the MFC-NAcc-Hip network in the treatment of subjects with SZ
by APDs, and led us to investigate their functional connectivity.
The neuronal network defined by these regions is recipro-
cally connected and is thought to be essential in regulating the
balance between limbic and prefrontal inputs in the service of goal-
directed behaviors (Mogenson et al., 1980; Grace, 2000; Gruber
et al., 2009). Goto and Grace (2008) have proposed that dopamine
release in the NAcc modulates the balance between the MFC and
Hip inputs, thus allowing adjustments in behavior in response
to environmental demands. Upon testing this model, they showed
that an acute perfusion of a DA D2 antagonist in the NAcc led to the
facilitation of MFC over Hip evoked responses (Goto and Grace,
2007). As predicted by this acute animal model, we observed an
increase in the strength of functional connectivity between MFC
and NAcc after 1 week of treatment. Also acutely, we observed a
decrease in functional connectivity between MFC and Hip. Most
remarkably, the strength of the functional connectivity between
MFC and Hip at week one was predictive of treatment response.
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FIGURE 2 | rCBF changes relative to 1 week of APD treatment after 6weeks of treatment. Increases in activation are shown in red, and decreases are
shown in blue. The significant decrease in activation in medial frontal areas shifted between week 1 and week 6 of treatment. The shift was most significant
during the decision task condition.
FIGURE 3 | Functional connectivity between regions of interest (ROI) at
three time points in antipsychotic drug treatment (vertical axis) while
performing three tasks and combined for all tasks (horizontal axis).
Graph nodes represent ROI; graph edge color indicates the significance of the
connection between nodes (p-value), for all connections with p<0.05. SZ0,
baseline; SZ1, 1 week of antipsychotic drugs treatment; SZ6, 6 weeks of
antipsychotic drug treatment; HIP, hippocampus; VS; ventral striatum/nucleus
accumbens; MFC, medial frontal cortex.
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Table 7 | Functional connectivity between regions of interest during three task conditions at baseline.
Task Areaa MFC LNAcc RNAcc LHIP RHIP
Rest dF=26 MFC 1.000
LNAcc 0.231 p=0.238 1.000
RNAcc −0.019 p=0.924 0.265 p=0.173 1.000
LHIP 0.416 p=0.028* 0.248 p=0.204 0.038 p=0.848 1.000
RHIP 0.514 p=0.005** 0.038 p=0.847 −0.266 p=0.171 0.700 p=0.000** 1.000
Sensorimotor control task dF=25 MFC 1.000
LNAcc 0.247 p=0.213 1.000
RNAcc −0.086 p=0.669 0.295 p=0.135 1.000
LHIP 0.188 p=0.349 0.296 p=0.134 −0.133 p=0.508 1.000
RHIP 0.364 p=0.062 0.069 p=0.734 −0.216 p=0.280 0.794 p=0.000** 1.000
Decision task dF=22 MFC 1.000
LNAcc 0.546 p=0.006* 1.000
RNAcc 0.071 p=0.743 0.247 p=0.244 1.000
LHIP 0.442 p=0.030* 0.378 p=0.068 −0.260 p=0.221 1.000
RHIP 0.572 p=0.003** 0.192 p=0.369 −0.378 p=0.068 0.721 p=0.000** 1.000
aValues reported are Pearson’s r and two-tailed significance. *p<0.05, **p<0.005.
PFC, prefrontal cortex; LNAcc, left nucleus accumbens, RNAcc, right nucleus accumbens; LHIP, left hippocampus; RHIP, right hippocampus; dF, degrees of freedom.
Table 8 | Functional connectivity between regions of interest during three task conditions at week one.
Task Areaa MFC LNAcc RNAcc LHIP RHIP
Rest dF=16 MFC 1.000
LNAcc 0.517 p=0.028* 1.000
RNAcc −0.013 p=0.959 0.265 p=0.288 1.000
LHIP 0.137 p=0.589 0.428 p=0.077 −0.047 p=0.852 1.000
RHIP −0.032 p=0.900 −0.093 p=0.713 −0.395 p=0.105 0.611 p=0.007* 1.000
Sensorimotor control task dF=14 MFC 1.000
LNAcc 0.447 p=0.083 1.000
RNAcc 0.092 p=0.736 0.262 p=0.326 1.000
LHIP 0.461 p=0.072 0.210 p=0.436 −0.219 p=0.415 1.000
RHIP 0.152 p=0.575 0.141 p=0.604 −0.425 p=0.101 0.823 p=0.000** 1.000
Decision task dF=15 MFC 1.000
LNAcc 0.719 p=0.001** 1.000
RNAcc 0. 038 p=0.885 0.253 p=0.326 1.000
LHIP 0. 385 p=0.127 0.470 p=0.057 −0.245 p=0.343 1.000
RHIP 0.045 p=0.862 0.280 p=0.277 −0.400 p=0.112 0.714 p=0.001** 1.000
aValues reported are Pearson’s r and two-tailed significance. *p<0.05, **p<0.005.
PFC, prefrontal cortex; LNAcc, left nucleus accumbens, RNAcc, right nucleus accumbens; LHIP, left hippocampus; RHIP, right hippocampus; dF, degrees of freedom.
We also observed changes after the first week that could not have
been predicted based on the acute D2 antagonist model.
Because all APDs are known to act directly at D2 receptors,
a primary site of APD action is believed to be the striatum. In
the NAcc, glutamatergic (GLU) inputs from the PFC and the
Hip, and DA inputs mainly originating from the ventral tegmen-
tal area (VTA) synapse on the same dendritic spines and shafts
of medium sized GABA-ergic projection neurons (Kotter, 1994;
Starr, 1995), creating a circuit that is ideal for the interaction of
Glu and DA inputs, and their modulation by APDs. Therefore, we
have hypothesized that one of the steps by which APD action is
achieved is through changes in functional connectivity within this
network, putatively restoring the balance between prefrontal and
limbic inputs.
How could APDs induce changes in functional connectivity?
Changes in long term plasticity (LTD and LTP) are thought to
result from changes in the spines’ structure of GABA neurons
via the interaction of DA and Glu (Wolf, 2003; Surmeier et al.,
2007; Shen et al., 2008). Putatively,APDs, by modifying the balance
between DA and Glu inputs at the level of the spines of GABA-ergic
neurons, could affect spines’ structure and induce plastic changes
affecting functional connectivity with other brain regions.
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Table 9 | Functional connectivity between regions of interest during three task conditions at week six.
Task Areaa MFC LNAcc RNAcc LHIP RHIP
Rest dF=24 MFC 1.000
LNAcc 0.296 p=0.142 1.000
RNAcc 0.150 p=0.142 0.438 p=0.025* 1.000
LHIP 0.185 p=0.367 0.428 p=0.029* −0.048 p=0.817 1.000
RHIP −0.039 p=0.851 0.052 p=0.799 −0.507 p=0.008* 0.734 p=0.000** 1.000
Sensorimotor control task dF=24 MFC 1.000
LNAcc 0.105 p=0.610 1.000
RNAcc 0.148 p=0.470 0.463 p=0.017* 1.000
LHIP −0.168 p=0.412 0.388 p=0.050* −0.105 p=0.609 1.000
RHIP −0.295 p=0.144 0.034 p=0.870 −0.579 p=0.002** 0.629 p=0.001** 1.000
Decision task dF=20 MFC 1.000
LNAcc 0.352 p=0.108 1.000
RNAcc −0.116 p=0.608 0.318 p=0.149 1.000
LHIP 0.271 p=0.223 0.542 p=0.009* 0.023 p=0.919 1.000
RHIP 0.126 p=0.576 0.178 p=0.428 −0.531 p=0.011* 0.656 p=0.001** 1.000
aValues reported are Pearson’s r and two-tailed significance. *p<0.05, **p<0.005.
PFC, prefrontal cortex; LNAcc, left nucleus accumbens, RNAcc, right nucleus accumbens; LHIP, left hippocampus; RHIP, right hippocampus; dF, degrees of freedom.
FIGURE 4 | Changes in functional connectivity between regions of
interest (ROI) during combined tasks from baseline to week one of
antipsychotic drug treatment (left), baseline to week six of antipsychotic
drug treatment (center), and between weeks one and six of
antipsychotic drug treatment (right). Graph nodes represent ROI; graph
edge color indicates the significance of the connectivity change between
nodes (p-value), for all connections with p<0.05. SZ0, baseline; SZ1, 1 week
of antipsychotic drugs treatment; SZ6, 6 weeks of antipsychotic drug
treatment; HIP, hippocampus; VS; ventral striatum/nucleus accumbens; MFC,
medial frontal cortex.
LIMITATIONS AND POTENTIAL CONFOUNDS
We did not study a healthy control group, so we were unable
to evaluate whether APDs normalized the pattern of functional
connectivity in the NAcc, Hip, MFC network.
A 2-week withdrawal is likely not enough to allow medication-
induced brain changes to fully revert to a baseline condition.
However, the potent rCBF increase observed in the dorsal and
ventral striatum by APDs in this study strongly suggested that DA
receptors were not blocked by residual medication.
We investigated the effect of APDs on a limited network of
interconnected regions (MFC-NAcc-Hip). This model is based
on a large body of clinical and preclinical data. The sub-
stantia nigra, which is an important part of the network dis-
cussed in this study, was not incorporated into the neural net-
work, although we clearly observed changes in its function with
treatment. Further studies are needed to investigate the role
of the substantia nigra in the APD-induced changes that we
observed.
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FIGURE 5 | Functional connectivity model. Functional connectivity
model of medial frontal cortex (MFC), and hippocampus (HIP)
incorporating gabaergic (red), glutametergic (green) and dopaminergic
(blue) projections with an emphasis on MFC and HIP projection
interactions in nucleus accumbens (NAcc). VP, ventral pallidum; Thal,
thalamus; VTA, ventral tegmental area.
Table 10 | Changes in functional connectivity between three time
points in antipsychotic drug treatment.
SZ1>SZ0 SZ6>SZ0 SZ6>SZ1
Medial frontal cortex to left nucleus accumbens
z -score 1.65 −0.78 −2.32
Significance a 0.0495* 0.2177 0.0102*
Medial frontal cortex to right nucleus accumbens
z -score 0.23 0.75 0.44
Significance a 0.4090 0.2266 0.3300
Medial frontal cortex to left hippocampus
z -score −0.09 −1.78 −1.49
Significance a 0.4641 0.0375* 0.0681
Medial frontal cortex to right hippocampus
z -score −2.56 −2.84 −1.00
Significance a 0.0052* 0.0023** 0.1587
Left nucleus accumbens to left hippocampus
z -score 0.49 0.98 0.39
Significance a 0.312 0.1263 0.348
Right nucleus accumbens to right hippocampus
z -score −0.77 −2.08 −1.08
Significance a 0.2207 0.0188* 0.1401
aOne-tailed significance. *p<0.05, **p< 0.005.
SZ0, baseline; SZ1, 1 week of antipsychotic drugs treatment; SZ6, 6 weeks of
antipsychotic drug treatment.
CONCLUSION
In order to evaluate changes in functional connectivity as a result of
treatment with APDs, we identified a limited number of regions
that have been implicated in the mechanism of action of APDs
and that are part of a neuronal network known to be modu-
lated by DA. Paralleling the time course of therapeutic response,
we found that APDs altered functional connectivity between
regions of this network after 1 week of treatment, and that further
changes unfolded after the next 5 weeks of treatment. Critically,
the strength of the functional connectivity between the MFC
and Hip after 1 week of treatment was predictive of treatment
response. This pattern of changes might represent an impor-
tant biomarker for indexing treatment response. The regulation
by APDs of the balance between prefrontal and limbic inputs to
the striatum through plastic changes may be crucial to restoring
adaptive behavior.
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